AMT Medical Laboratory Technician Study Guide

1. Patient identity and result traceability

A result is useful only when it can be traced to the right patient and order. Compare the identifiers on the collection label, request and laboratory record before analysis; a matching name alone cannot resolve a conflicting medical record number. If an identifier is missing or inconsistent, hold the specimen and investigate through the laboratory's documented process. Do not infer identity from the test requested or quietly replace a label. Record who resolved the discrepancy, what evidence supported the decision and when the change occurred, so the original and corrected information remain traceable. At reporting, check that results entered through instruments or interfaces reached the intended record. The related medical laboratory technician study guide can help you practice following a specimen through these steps.

Worked example: A chemistry tube is labeled for Morgan Lee, medical record number 4821, but the matching order lists Morgan Lee, number 4281. Hold testing despite the shared name: either identifier could belong to another patient. Compare the collection documentation and contact the appropriate source to resolve identity. If the discrepancy cannot be reliably resolved, obtain a new specimen; document any accepted correction with its audit trail.

Watch the distinction: A familiar patient name does not make a mismatched tube safe to test. The conflicting identifier breaks the link between specimen and patient until verified.

Reference: [2]

2. Collection choices and patient preparation

Collection decisions begin with the requested analyte and method. Additives serve different purposes: EDTA binds calcium for cellular testing, citrate preserves coagulation factors in a defined blood-to-additive mixture, and some chemistry tests use serum or a specified plasma matrix. An underfilled additive tube changes that mixture; carryover from a preceding tube can alter measurements in the next one. Patient conditions matter too. Food intake, posture, recent exercise, dose timing and a nearby infusion can change the sample before it reaches the analyzer. Review the order and collection record when a pattern is physiologically surprising. A plausible artifact does not prove that the patient's value is normal. Establish how the specimen was obtained, assess whether the method can use it, and recollect correctly when contamination remains possible.

Worked example: A chemistry specimen drawn after an EDTA tube has elevated potassium and unexpectedly low calcium. The collection note also records an active infusion near the draw site. Potassium-containing EDTA carryover could raise potassium and bind calcium; infusion contamination could distort several analytes. Review the collection sequence and site, then obtain a properly collected specimen before interpreting either result.

Watch the distinction: High potassium with low calcium is not automatically an EDTA error. A nearby infusion offers another preanalytic explanation, and the patient may also have a genuine abnormality.

3. Specimen processing and interference

Specimen quality changes with time and handling. Before cells are separated, they continue metabolizing glucose, so a processing delay can lower measured glucose. Cell rupture releases intracellular contents, including potassium, and hemoglobin may interfere with some optical methods. Lipemia scatters light; bilirubin can affect reactions or absorbance at method-dependent wavelengths. These appearances are clues to possible analytical interference, not diagnoses by themselves. Check collection time, transport conditions, centrifugation, separation and storage against the assay's validated requirements. If an aliquot is made, preserve its connection to the original tube and avoid transferring cells or contamination. Compare any interference index or visual finding with the method's stated limits before deciding whether a result can be reported, qualified or requires a new specimen.

Worked example: An unseparated blood tube reaches glucose testing several hours after collection. A second tube is visibly hemolyzed before potassium analysis. Continued cellular glucose use could lower the first result; cell rupture could raise potassium in the second. Check each method's interference and stability limits. If those limits are exceeded, request suitable specimens rather than treating the displayed values as patient physiology.

Watch the distinction: A hemolyzed tube does not prove the patient's potassium is high, and a delayed glucose result does not prove it is low. Handling can create either pattern.

Reference: [2]

4. Safety and equipment readiness

Treat blood and other potentially infectious material as exposure hazards throughout collection, transport and analysis. Use appropriate barriers, safe sharps devices, designated disposal containers and the worksite exposure procedure. If a sharp or splash exposure occurs, promptly clean or flush the affected area, report it and seek the required occupational assessment. Equipment readiness is part of safety and result quality: confirm pipette performance, balance calibration, centrifuge condition, microscope optics and monitored temperatures before relying on them. An abnormal sound, vibration or temperature excursion is a reason to stop affected work and assess specimens or reagents. For a breakage inside a centrifuge, control access and follow the containment procedure before opening or cleaning it. OSHA's bloodborne pathogen guidance explains the role of exposure controls and protective equipment.

Worked example: A centrifuge begins vibrating strongly. After the run stops, a blood tube is found broken inside. Keep others away, allow the laboratory's containment procedure to govern opening and cleanup, and use the specified protection. Document the event, assess affected specimens for loss or contamination, and inspect the centrifuge before it returns to service.

Watch the distinction: A centrifuge that still spins is not necessarily fit for use. Strong vibration or a broken tube can compromise containment, specimen quality and instrument performance.

Reference: [3]; [2]

5. Dilutions, units and reagent preparation

A dilution factor compares final mixture volume with the volume of original sample in that mixture. Add every component before calculating: dilution factor equals total volume divided by sample volume, and original concentration equals measured diluted concentration times that factor. The diluted reading must itself fall inside the assay's validated measuring interval. For reagent preparation, use conservation of analyte, often written C1V1 = C2V2 when the same concentration units and compatible volumes are used. Unit conversions require an explicit factor and careful cancellation of units; a change from milliliters to liters alone introduces a factor of 1,000. Record whether a ratio such as 1:10 means one part sample in ten total parts, because that convention prevents a common one-part error. Check that calculated concentrations and final volumes are physically plausible.

Worked example: Mix 0.20 mL sample with 1.80 mL diluent. The final volume is 2.00 mL, so the factor is 2.00/0.20 = 10, a 1:10 dilution. The diluted specimen measures 3.2 U/L within the validated interval. The original concentration is 3.2 × 10 = 32 U/L, assuming the assay's dilution procedure preserves recovery.

Watch the distinction: Adding nine parts diluent to one part sample makes a tenfold dilution. Multiplying by nine uses only the diluent volume and understates the original result.

6. Analytical and diagnostic performance

Analytical performance and diagnostic classification answer different questions. Accuracy describes closeness to a reference value; precision describes how closely repeated measurements agree. A detection limit concerns the smallest signal reliably distinguished from background, while the measuring interval identifies concentrations the method can quantify under its validated conditions. A reference interval describes results in a defined reference population and is neither a detection limit nor a diagnostic cutoff. Diagnostic sensitivity is true positives divided by all people with the condition; specificity is true negatives divided by all people without it. Positive and negative predictive values instead condition on the test result and depend on prevalence in the tested group. When evaluating a study, check how the reference diagnosis was established and whether its patients resemble those in whom the test will be used.

Worked example: A comparison set contains 80 true positives, 20 false negatives, 90 true negatives and 10 false positives. Sensitivity is 80/(80 + 20) = 80%; specificity is 90/(90 + 10) = 90%. Positive predictive value is 80/(80 + 10) = 88.9%. These figures describe this group's classifications, not the assay's lowest detectable concentration.

Watch the distinction: An assay can detect a tiny concentration yet have modest diagnostic sensitivity. Detecting analyte and correctly classifying patients depend on different limits and cutoffs.

7. Control failures and the quality cycle

Controls test whether an analytical system is behaving as expected before patient results are released. An isolated outlier may suggest random error; a sustained move to one side of the mean suggests a shift; a progressive rise or fall suggests a trend. Apply the laboratory's stated acceptance rules rather than treating every visible fluctuation as failure. When controls fail, hold affected results, examine reagent lots, calibration, maintenance and handling, then repeat controls after correction. The investigation extends backward to patient results produced since the last evidence of acceptable performance. Document the cause, action and impact assessment. Proficiency testing provides an external check, while preanalytic and postanalytic reviews catch identification and reporting errors controls cannot detect. CDC's laboratory quality overview describes this wider quality system.

Worked example: After a reagent lot change, both low and high controls move upward and exceed the laboratory's stated acceptance rule. Their shared direction suggests a systematic shift. Hold patient results, verify lot setup and calibration, correct the cause, and rerun controls. Review results generated since the last acceptable controls; amend any already reported values shown to be affected.

Watch the distinction: Repeating a failed control until one value passes does not explain a shift. A common change across control levels calls for cause finding and patient-result review.

Reference: [2]

8. Signals, calibration and measuring limits

In an absorbance assay, the instrument compares transmitted light with a blank or reference, then uses calibration to relate signal to concentration. Fluorescence measures emitted light after excitation; turbidimetry and nephelometry measure effects of particle scatter. Electrodes convert chemical activity into electrical potential, while chromatography and electrophoresis separate substances before measurement. Immunoassays use selective binding but remain vulnerable to cross-reactivity and other interference. The direction of signal change depends on the specific method, so read its reaction design before inferring a concentration. Check blank and calibration validity, reagent condition, reaction timing and quality controls. A reading beyond the validated measuring interval cannot be treated as an exact number. A permitted dilution requires both an in-range diluted result and evidence that the analyte recovers appropriately after dilution.

Worked example: An endpoint absorbance assay displays a patient result above its validated interval after a high-concentration sample. First check controls and possible carryover. Under a validated 1:4 dilution procedure, an in-range diluted result of 38 U/L gives 38 × 4 = 152 U/L. Report that value only if the method permits the dilution and its recovery checks pass.

Watch the distinction: A digital display can show a number outside the calibrated interval. The extra digits do not make that extrapolated result quantitatively valid.

9. Glucose and renal measurements

Blood glucose is vulnerable to continued cellular consumption after collection; separation and any preservative must match the method and timing requirements. For renal measurements, urea and creatinine reflect more than filtration alone: production, muscle mass, diet, hydration and specimen conditions can affect their concentrations. A timed creatinine clearance estimates the plasma volume cleared per minute from urine creatinine concentration, urine flow and paired plasma creatinine. Use clearance = urine concentration × urine flow / plasma concentration, with both concentrations in the same units. Calculate flow from the total urine volume and collection duration, then check completeness and whether plasma collection represents that interval. The estimate is affected by collection error and creatinine handling, so it should be interpreted as a laboratory estimate rather than an exact measurement of filtration.

Worked example: Urine creatinine is 80 mg/dL, with 1,440 mL collected over 24 hours; plasma creatinine is 1.0 mg/dL. Flow is 1,440 mL/1,440 min = 1 mL/min. Clearance is (80 mg/dL × 1 mL/min)/(1.0 mg/dL) = 80 mL/min. Confirm collection completeness before interpreting this estimate.

Watch the distinction: A correct clearance equation cannot repair a missed urine portion. An incomplete collection lowers measured total excretion and can make the clearance estimate misleading.

10. Electrolytes and acid-base calculations

Electrolyte interpretation begins with specimen quality and the measurement method. Hemolysis can release intracellular potassium, and fluid drawn near an infusion can dilute or add solutes. Anion gap summarizes measured cations minus selected measured anions; with the supplied equation Na − (Cl + HCO3), a larger value indicates unmeasured anions relative to those terms. Compare it only with the interval specified for that equation and laboratory. Acid-base interpretation then follows a sequence: assess blood pH, identify the direction of carbon dioxide and bicarbonate changes, determine the primary process, and check whether any accompanying response fits the stated clinical or case criteria. Confirm specimen type and collection conditions because air exposure, delay and anticoagulant effects may distort blood-gas values. One calculated gap cannot establish the cause of an acid-base disturbance.

Worked example: A case supplies Na 140, Cl 104 and HCO3 18 mmol/L, with an anion-gap interval of 8 to 12 mmol/L. Using Na − (Cl + HCO3), the gap is 140 − (104 + 18) = 18 mmol/L, above that interval. Review the paired blood gas and specimen quality before interpreting the source of the unmeasured anions.

Watch the distinction: An elevated gap does not identify a specific toxin or disease. It signals an imbalance in the measured equation that requires valid data and clinical correlation.

11. Hepatic, cardiac and pancreatic patterns

Interpret chemistry markers as patterns tied to tissue processes and collection time. Predominant aminotransferase increases suggest hepatocellular injury, whereas alkaline phosphatase and gamma-glutamyl transferase rising with conjugated bilirubin support a cholestatic pattern. Albumin and total protein add information about synthesis, loss or inflammation but change on different time scales. Enzyme activity alone is rarely tissue-specific. Cardiac markers are especially time dependent: compare results from appropriately timed specimens using the assay's method and stated decision criteria, and investigate interference or mismatched specimens if the trend is implausible. Pancreatic markers also need clinical context and method-specific interpretation. The technician verifies analytical validity, recognizes a pattern and escalates findings according to the laboratory pathway; a marker pattern does not by itself establish a definitive diagnosis.

Worked example: A specimen shows raised conjugated bilirubin, alkaline phosphatase and gamma-glutamyl transferase, with smaller aminotransferase changes. This supports a cholestatic laboratory pattern. In another series, a cardiac marker rises between two correctly timed specimens. Verify the identities, controls and assay conditions, then flag the change for review under the stated protocol rather than diagnosing from either value alone.

Watch the distinction: A single raised enzyme is not a map to one organ. Tissue distribution, marker timing and accompanying results determine how specific the laboratory pattern is.

12. Lipids, protein fractions and iron studies

A calculated lipid fraction is useful only under the equation's stated conditions. Check specimen status, units, triglyceride concentration and method limitations before applying it; otherwise request a supported direct measurement or report the components without a calculated value. Protein electrophoresis separates proteins by migration and shows distribution patterns. A narrow peak suggests a concentrated protein fraction needing further characterization; a broad increase can reflect a varied immunoglobulin response. Neither pattern alone identifies a disease. Iron studies also require combinations: low ferritin with reduced circulating iron often supports depleted iron stores, while inflammation can lower circulating iron despite preserved or raised ferritin. Transferrin-related measures and the clinical context help distinguish these patterns. Compare results from the same episode and check analytical validity before connecting them.

Worked example: A case permits LDL calculation in mg/dL under its stated conditions. Total cholesterol is 200, HDL is 50 and triglycerides are 150 mg/dL. Using LDL = total − HDL − triglycerides/5 gives 200 − 50 − 30 = 120 mg/dL. If the specimen violates the case's validity rule, do not use 120 as a reported calculated result.

Watch the distinction: Low serum iron alone does not establish iron deficiency. Inflammation can also reduce circulating iron, so ferritin and other supplied findings must be considered.

13. Endocrine results in context

Hormone concentrations depend on feedback, timing and physiological state. Thyroid-stimulating hormone and thyroid hormones are interpreted together because pituitary feedback changes the expected pattern. Cortisol has a daily rhythm, making collection time essential when applying a reference interval. Reproductive hormones vary with age, cycle phase, pregnancy and treatment. Use the interval validated for the assay, specimen type and relevant patient context. Immunoassays can produce misleading values when binding proteins, heterophile antibodies, supplements or medications interfere, depending on the method. A discordant result calls for identity and control checks, review of collection details and, where appropriate, an alternate method or repeat specimen. The technician should identify the conflict and route it for interpretation rather than convert one out-of-context hormone value into a diagnosis.

Worked example: A cortisol specimen is collected at 4 p.m., but the request displays a morning reference interval. Comparing the result with that interval would be unsound because expected cortisol changes during the day. Record the actual collection time, use the applicable assay interval, and review supplied medication or interference information before offering a laboratory interpretation.

Watch the distinction: A hormone value is not simply high or low in isolation. Collection time, physiological state and assay-specific intervals can change the comparison.

14. Drug monitoring and toxicology

Therapeutic drug monitoring depends on when the specimen was collected relative to dosing. A trough is taken at the defined point before the next dose; a sample shortly after dosing represents a different pharmacokinetic phase. Record the dose, collection time and specimen matrix before comparing a concentration with a target interval. Unexpected values may also reflect missed doses, altered distribution, assay interference or sample contamination. Toxicology immunoassays are often screening methods: an antibody may bind a related compound, so a positive result is presumptive. A more specific method, commonly one that separates and identifies compounds, can resolve the target when required. Likewise, a negative screen only excludes detection above that method's cutoff for the substances it covers. The technician reports the analytical finding and limitations without inferring exposure timing or impairment.

Worked example: A drug level is drawn 30 minutes after a documented dose, although the order requests a trough immediately before the next dose. Record the actual timing and avoid comparison with the trough interval. Separately, a urine immunoassay screen is positive with a known possible cross-reacting medicine; report it as presumptive and follow the specified confirmation pathway.

Watch the distinction: A precisely measured drug concentration can still answer the wrong question if collection timing is wrong. Analytical accuracy does not make a postdose value a trough.

15. Blood-cell development and specimen quality

Red cells mature from marrow precursors into oxygen-carrying cells, while reticulocytes provide a window into recent production. Leukocyte lineages specialize in defense, and megakaryocytes shed platelets that support primary hemostasis. A complete blood count can reflect these processes only if the specimen remains suitable. EDTA prevents clotting by binding calcium, but the tube must be filled as intended and mixed promptly and gently so anticoagulant contacts the blood. A clot can trap platelets and leukocytes, causing falsely low counts. Aging and poor storage can alter cell size, shape and staining, making morphology less reliable even when an analyzer still produces numbers. Inspect the tube and review collection time, storage and analyzer flags before interpreting an unexpected count or film.

Worked example: An EDTA tube contains a small visible clot, and the automated platelet count is low. Platelets may be trapped in the clot, so the count cannot reliably represent the patient. Hold the result and recollect according to the specimen procedure. If the new specimen is well mixed and unclotted, evaluate its count and film on their own merits.

Watch the distinction: A small clot is not harmless because the rest of the tube looks liquid. Cell trapping can invalidate a count without blocking the analyzer.

16. Automated counts and implausible CBCs

Automated counters infer cell number and size from measurable signals. Impedance instruments count electrical pulses as cells pass through an aperture; pulse size relates to particle volume. Optical systems classify cells using light scatter and, in some methods, staining. Hemoglobin is measured after red-cell lysis by a separate photometric reaction, so it may remain comparatively stable when a red-cell count is distorted. Always inspect flags, distributions and internal CBC relationships. Cold agglutinins can clump red cells: one aggregate may be counted as one large particle, lowering RBC count and raising apparent MCV. Derived indices such as MCHC can then become implausible. Platelet clumps, lipemia and incomplete lysis produce different artifacts. Resolve the mechanism with a film and validated repeat procedure before releasing corrected values.

Worked example: A CBC shows a very low RBC count, high MCV and implausibly high MCHC, with a cold-agglutinin flag. Red-cell aggregates could be counted as fewer, larger particles while measured hemoglobin changes less. Examine the film and use the validated warming and rerun procedure. Interpret the indices only after the interference is resolved or clearly documented.

Watch the distinction: An analyzer flag is not a diagnosis, but it is not disposable noise. Implausible relationships among RBC count, hemoglobin and hematocrit demand investigation.

17. Red-cell indices and anemia patterns

Red-cell indices turn CBC measurements into size and hemoglobin-content clues. With hematocrit in percent and RBC count in millions per microliter, MCV in femtoliters equals hematocrit × 10 / RBC. MCH in picograms equals hemoglobin in g/dL × 10 / RBC. MCHC in g/dL equals hemoglobin × 100 / hematocrit. Check that the indices agree with the blood film and with one another before interpreting them. Small pale cells and low ferritin can support an iron-deficiency pattern; large cells with compatible vitamin findings suggest a different process. Mixed cell populations may produce a near-normal average despite abnormal morphology. The MLT practice questions offer further opportunities to combine calculations with film and chemistry clues.

Worked example: Hemoglobin is 9.0 g/dL, hematocrit 30%, and RBC count 4.0 million/µL. MCV is 30 × 10/4.0 = 75 fL; MCH is 9.0 × 10/4.0 = 22.5 pg; MCHC is 9.0 × 100/30 = 30 g/dL. With low ferritin and small pale cells, these support an iron-deficiency pattern, subject to clinical review.

Watch the distinction: A low MCV does not by itself prove iron deficiency. Compare ferritin, morphology and other supplied findings, and investigate discordant indices for artifact.

18. Reticulocytes, hemolysis and hemoglobin variants

Reticulocytes are recently released red cells, so their proportion helps assess marrow response to anemia. A raw percentage can look high simply because mature red cells are depleted. A corrected reticulocyte percentage adjusts for the patient's hematocrit using a stated reference hematocrit: raw percent × patient hematocrit / reference hematocrit. Further maturation adjustment requires an explicitly supplied factor. Increased production may accompany blood loss or hemolysis, but interpret it alongside bilirubin fractions, lactate dehydrogenase, haptoglobin and film findings. Hemoglobin separation methods identify fractions by migration or another physical property; co-migration and recent transfusion can complicate interpretation. An unusual fraction is a finding for confirmation and context, not a complete genotype or disease diagnosis from one tracing.

Worked example: A patient has reticulocytes of 6% and hematocrit of 24%; the case supplies 45% as the reference hematocrit. Corrected reticulocytes equal 6 × 24/45 = 3.2%. This indicates increased production relative to the low hematocrit. If indirect bilirubin is raised, haptoglobin low and the film shows red-cell damage, the combined findings support evaluation for hemolysis.

Watch the distinction: A raw reticulocyte percentage overstates marrow response in anemia because its denominator is reduced. Correct for hematocrit before comparing production patterns.

19. White-cell differential and abnormal-cell review

A differential percentage describes composition, whereas an absolute count combines that percentage with the total WBC count. Multiply WBC by the cell fraction, keeping units consistent. This matters because a high percentage can coexist with a low absolute count when total WBC is low. Review analyzer flags and the blood film for immature or abnormal cells before accepting an automated classification. Toxic granulation, cytoplasmic vacuoles and a left shift can occur in reactive states, but their interpretation depends on the full picture. Blasts or other suspicious cells need documented review; an infection history does not explain them away. A technician can verify morphology, calculate absolute counts and escalate findings through the laboratory's review pathway without assigning a marrow diagnosis from a single specimen.

Worked example: WBC is 12.0 × 10^9/L and neutrophils are 75%, so the absolute neutrophil count is 12.0 × 0.75 = 9.0 × 10^9/L. Toxic granulation with a supplied infection history supports a reactive interpretation of those cells. A separate blast flag still requires film review and appropriate escalation rather than being folded into the reactive explanation.

Watch the distinction: Seventy-five percent neutrophils does not state the absolute count. Always multiply by total WBC, then inspect suspicious flags separately.

20. Platelets and manual cell counts

Before interpreting thrombocytopenia, check whether platelets are dispersed or clumped on the film. EDTA-associated clumping can make an analyzer exclude aggregates from the platelet channel, producing pseudothrombocytopenia; giant platelets may also be misclassified. Follow the validated investigation method and do not replace one questionable count with an unsupported estimate. For a manual chamber count, the core relationship is cells counted × dilution factor / counted volume in microliters. The dilution factor must represent final volume divided by original specimen volume, and the chamber volume must include the counted area and depth. Mix the diluted suspension, allow cells to settle, apply a consistent boundary rule and examine both counting sides when the procedure requires it. Uneven distribution or debris can defeat otherwise correct arithmetic.

Worked example: An automated platelet count is low, but the smear shows platelet clumps. Investigate pseudothrombocytopenia before reporting the count as true thrombocytopenia. In a separate manual exercise, 100 cells are counted in 0.1 µL of a 1:20 dilution. The undiluted concentration is 100 × 20/0.1 = 20,000 cells/µL, assuming representative mixing and a valid chamber count.

Watch the distinction: Multiplying a chamber count by the dilution factor alone omits counted volume. The result must also be divided by the actual chamber volume.

21. Film quality and deeper hematology studies

Choose the thin area just behind a blood film’s feathered edge, where red cells mostly touch without overlapping. A thick region can make cells look smaller or darker and hide inclusions; a poor stain can distort nuclear detail. Scan at low power for distribution and platelet clumps before performing a systematic differential in the suitable zone. The erythrocyte sedimentation rate reflects how quickly red cells settle under specified conditions. Increased plasma proteins can promote rouleaux and faster settling, but anemia, cell shape and handling also affect it, so it is nonspecific. Persistent unexplained immature cells may lead to marrow examination. Cytochemical stains reveal selected cellular enzyme activity, while immunophenotyping identifies surface or intracellular markers. Neither replaces morphology, history and specialist interpretation. The related medical laboratory scientist certification guide offers further study of these investigations.

Worked example: A film is thick from head to tail, and red cells overlap in every available field. Its apparent hypochromia and differential count cannot be trusted. Prepare and stain another film, then choose a suitable counting area. If well-made films from repeated specimens still show circulating immature cells, record their features and refer the finding for review; marrow and immunophenotypic studies may clarify their lineage.

Watch the distinction: Counting more fields cannot repair a film with no suitable examination area. Thickness changes apparent morphology and obscures cells, so prepare a usable film before interpreting it.

22. Hemostatic pathways and screening assays

At an injured vessel, platelets adhere, activate and aggregate to form an initial plug. Coagulation reactions then generate thrombin, which converts fibrinogen to fibrin and stabilizes that plug. Antithrombin and the protein C system limit clot formation; plasmin later breaks down fibrin. Screening assays isolate portions of this network in a tube. Prothrombin time, or PT, is especially sensitive to the tissue-factor and common pathways, while activated partial thromboplastin time, or aPTT, probes the contact-activated and common pathways. Thrombin time assesses the final conversion of fibrinogen to fibrin and can be affected by thrombin inhibitors. A fibrinogen assay estimates available functional substrate; fibrin-degradation assays indicate breakdown products but do not establish their cause. Interpret an abnormal time alongside specimen quality, anticoagulant exposure and the method’s stated interval.

Worked example: A patient’s PT is 12 seconds within the supplied 10 to 14 second interval, while aPTT is 58 seconds against a supplied 25 to 38 second interval. The isolated aPTT prolongation directs attention to assay-sensitive factors, inhibitors or anticoagulant effects. First verify citrate fill and ask about anticoagulant exposure; a factor deficiency cannot be assigned from these two screening results alone.

Watch the distinction: A normal PT does not prove that coagulation is normal. PT and aPTT test overlapping but different reaction pathways, and neither measures platelet plug formation directly.

23. Citrate specimen validity

A coagulation tube contains citrate that binds calcium during transport. The analyzer adds calcium back in a controlled amount to start clotting, so the intended blood-to-citrate ratio matters. Underfilling leaves excess citrate relative to plasma; after recalcification, residual binding can falsely lengthen clot times. A clot consumes factors and platelets, making the specimen unsuitable even if the analyzer produces a number. Delayed processing can also change labile factor activity or permit ongoing cellular effects. Mark the collection and processing times, inspect the fill and specimen, and separate plasma as required by the method. With a markedly high hematocrit, plasma volume is reduced relative to whole blood; use the laboratory’s supplied citrate-adjustment calculation before collection when indicated. Document the basis for rejection or adjustment rather than correcting a suspect result mathematically afterward.

Worked example: An aPTT is 61 seconds against the case interval of 25 to 38 seconds, but the citrate tube is visibly below its fill mark. Excess citrate may explain the prolongation, so hold the result and request a correctly filled specimen. If the replacement tube yields 32 seconds with valid controls, report 32 seconds; the initial 61 seconds was not interpretable.

Watch the distinction: Do not multiply an underfilled tube’s aPTT by a correction factor. The altered calcium balance changes the clotting reaction itself, and a calculated adjustment cannot validate that specimen.

24. PT, INR and vitamin K antagonist monitoring

PT is the elapsed time from adding tissue-factor reagent and calcium to forming a detectable clot. Vitamin K antagonists reduce functional vitamin K-dependent coagulation factors, commonly prolonging PT. Because PT varies with reagent sensitivity, the international normalized ratio uses the patient PT, the method’s mean normal PT and its international sensitivity index, or ISI: INR = (patient PT / mean normal PT)^ISI. Keep both PT values in the same units before forming the dimensionless ratio. Verify identity, citrate specimen quality, controls and the correct reagent ISI before reporting. INR standardizes vitamin K antagonist monitoring more effectively than an unadjusted PT, but it does not turn every prolonged PT into evidence of that treatment. Interpretation and any action require the patient’s documented treatment context and the applicable clinical plan.

Worked example: A patient receiving a vitamin K antagonist has PT 24 seconds. The reagent’s mean normal PT is 12 seconds and its ISI is 1.0. The ratio is 24/12 = 2.0, so INR = 2.0^1.0 = 2.0. With acceptable specimen and controls, report the INR; whether it meets the patient’s intended range depends on the supplied treatment plan.

Watch the distinction: A PT ratio is not always the INR. When ISI differs from 1.0, raise the ratio to that ISI; use the value assigned to the reagent in service.

25. Mixing-study patterns

A mixing study combines equal volumes of patient plasma and normal plasma, then repeats the prolonged assay. Normal plasma supplies clotting factors. If the mixture corrects by the laboratory’s stated criterion and stays corrected after incubation, a factor deficiency becomes more likely. Persistent failure to correct suggests an inhibitor or drug interference. Correction immediately followed by loss of correction during incubation can indicate a time-dependent inhibitor. The exact boundary between correction and noncorrection depends on the assay and stated rule; visual comparison alone is insufficient. Also review heparin, direct anticoagulants, specimen contamination and baseline clot times before interpreting the pattern. A mix narrows the investigation; factor assays, inhibitor testing or drug-sensitive methods may still be required. Report the observed behavior without naming a specific inhibitor from the screen alone.

Worked example: A patient aPTT is 72 seconds. Under a hypothetical case rule, a mixed aPTT of 40 seconds or less counts as corrected. The immediate 1:1 mix is 36 seconds, but after incubation it is 65 seconds. It initially corrects and then loses correction, a time-dependent inhibitor pattern. Check drug exposure and proceed with the laboratory’s specified confirmatory testing.

Watch the distinction: Immediate correction does not end the investigation when an incubated mix is required. Some inhibitors act over time, so a later prolonged result can change the working interpretation.

26. Platelet function, consumption and fibrinolysis

Primary hemostasis depends on platelet number and function; coagulation supplies fibrin; fibrinolysis removes fibrin after clot formation. Evaluate these processes together when bleeding or consumption is suspected. Falling platelets can reflect consumption but also collection artifact, destruction or reduced production. Prolonged PT and aPTT suggest reduced or inhibited activity in pathways measured by those assays. Falling fibrinogen may indicate use exceeding replacement, while increased fibrin-degradation products show fibrin or fibrinogen breakdown, depending on the test. A rising degradation marker by itself is nonspecific. Look for a coherent trend, valid controls, specimen integrity and the method’s reference information. Report and escalate a verified urgent pattern through the laboratory’s established route; determining its clinical cause belongs to the treating team. A normal screening time also does not exclude every platelet-function disorder.

Worked example: On two valid samples, platelets fall from 180 to 70 × 10^9/L. The later sample has prolonged PT and aPTT, fibrinogen below the supplied interval and an increased fibrin-degradation marker. The combined change supports a consumption pattern more strongly than any one result. Verify the sample and controls, review the trend and communicate the urgent findings under the stated procedure.

Watch the distinction: An elevated degradation marker alone does not diagnose a consumption disorder. It can rise in other settings, and its meaning changes with platelet, clotting-time and fibrinogen findings.

27. Anticoagulants and assay interference

Different anticoagulants act at different points in coagulation, and routine clotting assays respond differently. Unfractionated heparin enhances antithrombin activity and often prolongs aPTT and thrombin time, though sensitivity is reagent dependent. Vitamin K antagonists reduce functional clotting factors and are commonly assessed with PT expressed as INR. Direct factor Xa inhibitors and direct thrombin inhibitors may alter PT or aPTT variably; a normal routine time cannot reliably exclude their presence. A prolonged time cannot be converted into a drug concentration without a validated drug-sensitive method. Determine the agent, last dose, specimen collection time and assay used. Distinguish treatment effects from heparin contamination of a line specimen. When drug measurement is requested, use the method and calibration appropriate to that drug and report within its validated limits.

Worked example: A patient taking a direct factor Xa inhibitor has aPTT 44 seconds against the case interval of 25 to 38 seconds. The laboratory’s reagent information states only variable sensitivity to this drug. The 44-second value shows prolongation in that assay, but it does not quantify exposure. Verify collection and medication history, then use a validated drug-specific method if concentration measurement is required.

Watch the distinction: A normal aPTT does not rule out a direct oral anticoagulant. Drug, concentration, sampling time and reagent sensitivity all affect the result, so use the appropriate method.

28. Hemostasis quality control and escalation

Clot detection may be optical or mechanical. Optical systems can misread highly turbid or otherwise interfering specimens, while either system depends on sound reagent preparation, temperature control and instrument performance. Run and assess the required control materials before releasing patient results. Failure at both normal and abnormal levels after a reagent change suggests a shared cause such as reconstitution, lot setup, calibration or instrument conditions; an isolated erratic result may suggest a different problem. Review control trends, reagent identifiers, maintenance records and specimen quality, then repeat controls after correction. Determine which patient samples were tested since the last acceptable controls and assess whether results require repeat testing or amendment. CDC laboratory quality guidance describes quality control and assurance as parts of the complete testing process. Escalate verified urgent findings promptly through the laboratory’s reporting path.

Worked example: After a new reagent lot, normal and abnormal controls both exceed the laboratory’s stated limits. A patient aPTT reads 95 seconds, but the run is invalid, so hold it and other affected results. Correct the lot setup, document the action and rerun controls. If controls pass and the patient repeat remains 94 seconds, verify and communicate that urgent result under the stated procedure.

Watch the distinction: A plausible patient result cannot override failed controls. The failure leaves analytical performance unverified; troubleshoot first, then reassess every affected result before release.

Reference: [2]

29. Immune mechanisms behind serology

Innate defenses act quickly through barriers, phagocytes and inflammatory proteins. Adaptive immunity adds antigen-specific B and T cell responses and immunologic memory. B cells may initially produce IgM and later produce class-switched antibodies such as IgG or IgA. IgM can bind multiple antigen sites efficiently and may activate complement; IgG can persist long after an exposure or vaccination. Complement activation can amplify inflammation and, in some settings, damage target cells. Serologic assays detect an antigen, an antibody or the interaction between them, so the target must be identified before interpreting a positive result. Antibody presence establishes an immune response under the assay’s conditions, not necessarily current infection. Consider collection timing, immune status and assay specificity. American Medical Technologists identifies the MLT credential, while the technical interpretation of each result depends on the particular laboratory method.

Worked example: An IgG antibody assay is positive six months after documented vaccination, while a current pathogen antigen assay is negative. The IgG result is consistent with an immune response that may persist; it does not establish active infection. Review the vaccine target and assay specifications before interpreting the antigen result, because a negative test only addresses detectable antigen in that specimen at that time.

Watch the distinction: Calling every IgM result a new infection is unsafe. Cross-reactivity, persistence and assay error can occur; compare timing and other evidence before assigning a stage of infection.

Reference: [1]

30. Serologic assay formats and controls

Serologic formats turn antigen-antibody binding into different visible or instrument signals. Agglutination forms clumps of particles or cells; precipitation forms complexes in solution or gel. Immunofluorescence uses a fluorescent label, whereas enzyme and chemiluminescent assays produce measurable light or color through labeled reactions. A lateral-flow device moves specimen across a membrane and captures target at a test line. These formats differ in analytical sensitivity, interference and whether results are qualitative, quantitative or semiquantitative. Start by checking the manufacturer’s controls and the laboratory’s acceptance rules. A qualitative cutoff separates reported categories for that method; it is not a universal boundary between disease and health. If a control fails, no patient line or numerical signal is reportable. Repeat with valid reagents or a valid device, then interpret the target detected, specimen type and timing together.

Worked example: A rapid antigen device shows a clear patient line but no control line. Because the control did not confirm proper flow and reagent activity, the entire test is invalid. Repeat using a new device and acceptable specimen. If the repeat has both control and patient lines, report target detected according to the device instructions, while recognizing that the result does not measure target concentration.

Watch the distinction: A strong patient line cannot rescue an absent control line. The failure means the device’s basic operation was not demonstrated, so its apparent patient reaction has no valid interpretation.

31. Titers and antigen-antibody excess

A titer is the reciprocal of the greatest specimen dilution that remains reactive under a defined method. For twofold serial dilutions, each step halves the concentration: 1:8, 1:16, 1:32 and so on. Record the final reactive dilution rather than averaging it with the first nonreactive tube. Antigen-antibody reactions also require a suitable proportion of binding partners. Antibody excess can produce a prozone effect, especially in lattice-based tests; antigen excess can cause postzone behavior. In certain sandwich immunoassays, very high antigen can saturate capture and detection antibodies separately, producing a high-dose hook effect and a deceptively low signal. A result that conflicts with the clinical or dilution pattern warrants controlled dilution and repeat testing under the assay instructions. Dilution may reveal interference, but it also changes the assay’s measurement limits.

Worked example: A sample is reactive at 1:8, 1:16, 1:32 and 1:64, then nonreactive at 1:128. The endpoint is 1:64, so the reported titer is 64 under this method. If the undiluted sample was unexpectedly nonreactive, the later reactivity suggests an excess-related effect; repeat the dilution series with controls before assigning that explanation.

Watch the distinction: The first nonreactive dilution is not the titer. Report the highest reactive dilution, and investigate an undiluted negative that becomes positive after dilution.

32. Cross-reactivity and discordant results

An immunoassay can produce a convincing signal without the intended target. Cross-reacting molecules may share an epitope with the target, while heterophile antibodies can bridge assay antibodies or block binding in unintended ways. Other specimen constituents may alter the signal or matrix behavior. When results disagree with another method or the clinical timeline, first verify specimen identity, controls, lot and instrument flags. Then compare what the assays actually detect; two tests with different targets need not agree at every stage. A repeat on the same platform checks reproducibility but may reproduce the same interference. Testing a new specimen, performing a validated dilution or blocking step, or using an alternate method can provide more independent evidence. Document the discrepancy and the resolution before assigning a qualitative interpretation or releasing an amended result.

Worked example: A qualitative assay is positive, but a second method targeting a different analyte is negative and the stated exposure occurred only yesterday. Identity and controls are correct. Review known cross-reactants and timing, then test a new specimen with the specified supplemental method. Until that work is complete, report only validated individual findings; the first positive alone does not settle the clinical interpretation.

Watch the distinction: Repeating the same immunoassay and obtaining another positive result does not exclude systematic cross-reactivity. An independent method or targeted interference check is more informative.

33. Infectious antigen and antibody timing

A pathogen antigen or nucleic-acid assay looks for material from the organism, while an antibody assay looks for the host response. These targets appear and disappear on different timelines. Soon after exposure, a person may have detectable pathogen material before producing antibody at a level the assay can detect. After clearance or vaccination, some antibodies may remain even when organism material is absent. Specimen site, collection quality, assay detection limits and treatment history also affect results. A negative early antibody test therefore has a different meaning from a negative test obtained after the expected response period. A positive nucleic-acid result establishes target detection in that specimen, not necessarily viable organisms or a complete clinical diagnosis. Check controls and contamination safeguards, report each analyte precisely, and use follow-up testing when the stated algorithm requires it.

Worked example: Five days after a documented exposure, a patient’s antibody assay is negative and a respiratory nucleic-acid assay is positive with valid controls. Antibody may still be below detection before seroconversion, so the negative antibody does not cancel the molecular finding. Report antibody not detected and nucleic acid detected for their respective specimens; clinical assessment determines the patient’s condition and next steps.

Watch the distinction: A positive antibody test does not automatically indicate active infection. It may reflect earlier exposure or vaccination, depending on the antigen tested and the timing.

34. Syphilis testing algorithms

Treponemal assays detect antibodies directed at Treponema pallidum antigens and may remain reactive after a past infection. Nontreponemal assays detect antibodies against lipid-associated antigens; their titers can help follow change over time but are not specific to one organism. In a reverse-sequence approach, a treponemal screen is followed by a nontreponemal test. If those disagree, the supplied algorithm may call for a different treponemal assay to clarify whether the first screen is likely to reflect treponemal exposure. In a traditional sequence, the starting and follow-up tests are reversed. Follow the stated sequence and report both the qualitative results and any valid titer. Serology alone cannot determine whether a patient has untreated, previously treated or newly acquired infection. Treatment history, symptoms and exposure information are needed for clinical classification.

Worked example: Under the case’s reverse-sequence algorithm, a treponemal screen is reactive, a nontreponemal test is nonreactive and a second treponemal assay is reactive. The two treponemal results support prior or present treponemal exposure. The nonreactive nontreponemal result does not identify treatment status or timing. Report the sequence accurately and flag the need for history and clinical assessment.

Watch the distinction: Do not call a reactive treponemal test proof of active disease. Antibody can persist after treatment, and a discordant sequence requires the specified follow-up and history.

35. Autoimmune, complement and allergy findings

Autoimmune tests detect different phenomena: autoantibodies identify immune recognition of self-antigens, inflammatory markers reflect a broader response, and complement tests measure either component concentration or pathway function. Complement can be consumed in vivo, but it can also change after poor specimen handling, so validity comes first. Total immunoglobulin measurements help assess broad production patterns; antigen-specific IgE indicates sensitization to a tested allergen, not the severity or certainty of a clinical reaction. Compare each result with its method-specific interval, specimen requirements and the other findings. A weak positive autoantibody may be nonspecific, especially when the stated assay has known background reactivity. If a result is unexpected, examine controls, storage and possible interference before repeating or referring it. The technician reports supported laboratory patterns and alerts the appropriate reviewer to significant discrepancies.

Worked example: A complement result is below the case interval and an autoimmune marker is positive, but the sample spent hours outside its validated handling conditions. In-vitro complement change is possible, so hold the complement interpretation and obtain a suitable repeat. If the repeat is also low with valid controls, report the confirmed pattern for clinical correlation; the antibody result alone does not establish disease.

Watch the distinction: Specific IgE positivity is not proof that an allergen caused the patient’s symptoms. It demonstrates sensitization under that assay and must be interpreted with the exposure history.

36. ABO forward and reverse grouping

ABO typing asks two reciprocal questions. Forward grouping tests patient red cells for A and B antigens with known antisera. Reverse grouping tests patient plasma against known A and B cells to detect the expected antibodies. For group A, cells carry A antigen and plasma generally reacts with B cells. Agreement provides a cross-check against specimen, reagent or interpretation errors. Discrepancies can arise from weak antibodies in very young patients, recent transfusion, unusual antigens, cold-reactive antibodies or technical error. Check identity and reagents, examine reaction strength and history, and resolve the discrepancy before assigning an issue-ready group. The strength and pattern matter: a weak or mixed-field reaction should not be rounded into a simple positive or negative. The technician documents the observed reactions and follows the transfusion service’s investigation and review pathway.

Worked example: Patient cells react 4+ with anti-A and 0 with anti-B. Patient plasma reacts 0 with A cells and 4+ with B cells. Forward and reverse groups agree with group A. On a second sample, the B-cell reverse reaction is unexpectedly weak; verify identity and reagent performance, then investigate age and transfusion history before finalizing that sample’s type.

Watch the distinction: Forward grouping alone is not a complete adult ABO interpretation when reverse grouping is expected. A discrepancy may reveal a clinically important identification or serologic problem.

37. Rh typing and mixed-field reactions

Routine Rh typing mainly asks whether red cells show the D antigen with the anti-D method in use. A clear positive or negative reaction can be interpreted only after checking controls and reagent performance. Weak reactions require attention to the laboratory’s method because variant D expression, recent transfusion or other conditions can affect the result. Mixed-field agglutination shows two visible red-cell populations, one agglutinated and one free. Recent transfusion with differently typed red cells is a common explanation, but it is not the only one. Review historical typing, component records, reaction appearance and any confirmatory testing specified by the service. Do not choose an Rh label for component issue by majority appearance. Resolve or formally manage the discrepancy under the service’s procedure and preserve the observed reactions in the record.

Worked example: A patient previously typed D negative received D-positive red cells during a documented emergency. Today, anti-D testing shows small agglutinates among many unagglutinated cells. That mixed-field pattern is compatible with two circulating red-cell populations. Compare the historical type and transfusion record, document the reaction and use the service’s discrepancy pathway before selecting further units.

Watch the distinction: Mixed-field anti-D is not simply a weak positive to round up. It may represent separate cell populations, so historical type and recent transfusion matter.

38. Antibody screens and identification panels

An antibody screen detects unexpected antibodies using reagent red cells with known antigen profiles. An identification panel adds more cells so the reaction pattern can be compared with antigen presence, phase and strength. A candidate specificity is supported when antigen-positive cells react and suitable antigen-negative cells do not. Rule out competing antibodies with appropriate nonreactive cells, paying attention to dosage: some antibodies react more strongly with cells carrying two copies of an antigen than with heterozygous cells. Patient transfusion and pregnancy history can raise concern for alloantibodies, while an autocontrol helps identify self-reactivity. Enzyme treatment can enhance some reactions and weaken or destroy others, so it changes the evidence rather than providing a universal confirmation. If the panel cannot exclude additional clinically significant antibodies, obtain selected cells or refer the investigation before declaring a final identification.

Worked example: Three E-positive panel cells react at the antiglobulin phase, including a homozygous E cell at 3+; three E-negative cells are nonreactive. Anti-E is the leading interpretation. Review nonreactive cells for adequate rule-outs of other antibodies, check the autocontrol and history, and use selected cells if needed. Reaction strength supports the pattern but does not independently prove specificity.

Watch the distinction: A matching panel pattern is a working identification until competing antibodies are excluded. Dosage can make a heterozygous cell falsely reassuring as a rule-out.

39. Antiglobulin methods and test validity

The direct antiglobulin test, or DAT, detects immunoglobulin or complement already attached to patient red cells in vivo. The indirect antiglobulin test, or IAT, incubates patient plasma with test red cells to detect antibodies that bind in vitro. In the tube IAT, washing removes unbound immunoglobulin before antihuman globulin is added; inadequate washing can neutralize that reagent and cause a false negative. Check cells coated with IgG must agglutinate when added to a negative tube antiglobulin test, demonstrating that active reagent remained and the procedure worked. Gel and solid-phase methods capture or display reactions differently and require their own controls and interpretation rules. Compare methods by their targets and validated performance, not by assuming identical reaction strength. An invalid negative must be repeated before it supports antibody screening or compatibility decisions.

Worked example: A tube IAT appears negative. After IgG-coated check cells are added, no agglutination occurs. The check-cell failure invalidates the negative result because functioning antihuman globulin was not demonstrated. Review wash steps, reagent addition and reagent condition, then repeat the IAT with valid controls. Do not use the original negative to clear a unit for issue.

Watch the distinction: A negative antiglobulin reaction is not automatically valid. In tube testing, failed check cells can expose omitted reagent, inadequate washing or inactive reagent.

40. Autoantibodies, eluates and adsorption

A positive autocontrol means the patient’s plasma reacts with the patient’s own red cells under the test conditions. Broad reactivity across screening cells can suggest an autoantibody, but it may also hide an alloantibody against donor-cell antigens. A DAT checks whether immunoglobulin or complement is bound to circulating cells; an eluate removes bound antibody for further testing. Adsorption removes selected antibody from plasma so residual reactivity can be examined. Method choice matters: after recent transfusion, the patient’s circulating cells may include donor red cells, making autoadsorption unsuitable for confidently excluding alloantibodies. Review transfusion history, DAT strength, hemolysis evidence and antibody records before selecting the investigation. If separation remains uncertain, refer the case. Do not assume all donor units are equally compatible merely because a warm autoantibody reacts broadly.

Worked example: A recently transfused patient has a panreactive screen, positive autocontrol and positive DAT. These findings support red-cell-bound and self-reactive antibody activity, but donor cells may also circulate. Review previous antibodies and hemolysis markers, then use the service’s appropriate adsorption or referral method to look for masked alloantibodies. Complete required antigen and compatibility checks before selecting units.

Watch the distinction: A positive autocontrol does not eliminate the possibility of an alloantibody. Broad autoantibody reactivity can mask a separate, clinically significant specificity.

41. Compatibility and specimen validity

Before issuing red cells, connect four records: the patient’s identifiers, the current specimen, the ABO and Rh results, and the antibody history. A negative current screen does not erase a previously identified clinically significant antibody. That antibody may have fallen below detection while memory cells remain capable of producing it after exposure. Select donor red cells that lack the corresponding antigen when required, and complete the applicable compatibility test. Check whether the specimen meets the laboratory’s current collection and validity requirements, particularly when recent transfusion or pregnancy could have changed the antibody picture. Resolve identification or grouping discrepancies before routine issue. The same traceability principles apply throughout medical laboratory technician certification. Document the unit selected, test results and review so another worker can reconstruct the decision.

Worked example: A group A patient has a negative current antibody screen, but the historical record shows anti-K. Two group A units are available: one K positive and one confirmed K negative. Select the K-negative unit for the required compatibility testing. Check the patient specimen’s collection time against the laboratory’s validity rule before issue. If it is no longer valid, obtain a new properly identified specimen.

Watch the distinction: A negative antibody screen means no antibody matters. Previously detected antibodies can become undetectable, so the documented history still guides antigen selection and compatibility testing.

42. Maternal antibodies and neonatal testing

Maternal IgG antibodies can cross the placenta and bind fetal red-cell antigens. A neonatal direct antiglobulin test, or DAT, detects immunoglobulin or complement already attached to the infant’s cells; it does not identify the antibody or measure the degree of hemolysis by itself. Interpret it alongside maternal antibody identification, the infant’s antigen status when available, bilirubin trend, hemoglobin and reticulocyte findings. Bilirubin can rise as sensitized cells are removed, but a positive DAT may occur without substantial disease, and hemolysis has other causes. Fetomaternal hemorrhage screening asks a different question: whether fetal cells entered maternal circulation. A positive screen leads to a validated quantitative assessment under the laboratory pathway. Keep maternal and neonatal samples clearly distinguished, and escalate concerning results to the responsible clinical team.

Worked example: A mother has identified anti-c, and her newborn’s c-positive red cells have a positive DAT. The infant’s bilirubin rises on successive specimens and hemoglobin falls. Together, these findings support immune red-cell destruction and need prompt review; the DAT alone would not establish severity. A separate positive maternal fetomaternal hemorrhage screen calls for the specified quantitative follow-up, not a treatment-dose calculation from the screen.

Watch the distinction: A positive neonatal DAT proves severe hemolytic disease. It shows red-cell sensitization; bilirubin, hemoglobin, timing and clinical assessment determine whether meaningful hemolysis is occurring.

43. Donor collection and traceability

Donor safety and recipient traceability begin before collection. Confirm the donor’s identity, link the history assessment to that person and assign a unique collection identity that follows the unit and every component made from it. Whole-blood collection takes a unit from which components may be prepared; apheresis selectively collects a component while returning others. Anticoagulant prevents clotting during collection, while preservative supports cell metabolism during storage. Infectious-disease screening reduces transmission risk, but a negative result cannot repair an identity error or eliminate every possible risk. Check collection records, labels, samples and processing links before a component becomes available. The American Medical Technologists MLT credential identifies the professional context; in practice, the technician documents discrepancies and keeps affected products unavailable while the authorized investigation resolves them.

Worked example: A red-cell unit passes its recorded infectious screening, but its bag number differs from the number on the donor collection record. Quarantine the unit and any linked components, check the original collection and processing records, and report the discrepancy through the service’s investigation path. Do not relabel by guessing which number is correct: neither acceptable appearance nor negative screening establishes the unit’s identity.

Watch the distinction: A tested unit is safe to release if its label seems like a clerical typo. Screening addresses particular infection risks; uncertain identity breaks traceability and requires resolution.

Reference: [1]

44. Component preparation and handling

Component preparation concentrates different therapeutic functions. Red-cell units primarily supply oxygen-carrying cells; platelets support primary hemostasis; plasma supplies soluble coagulation proteins; and cryoprecipitate concentrates selected proteins, including fibrinogen. These products have different handling requirements because their contents and preparation differ. At receipt and issue, compare the unit identifier, component type, ABO and Rh information when applicable, expiration, required modifications and visible condition with the records. A return to inventory requires evidence that the component remained within the service’s stated time, temperature and transport conditions. An intact appearance cannot prove those conditions. Conversely, a valid temperature log cannot repair an unreadable identity label. Hold an uncertain component, document its chain of custody and let the authorized disposition process decide whether it can be used.

Worked example: A platelet component returns after an unused issue. Its label is torn across the unit identifier, and no transport temperature record accompanies it. The bag looks normal, but both identification and handling evidence are incomplete. Place it on hold, compare issue and return records, and seek the missing documentation. If the service’s stated acceptance conditions cannot be verified, do not return it to available inventory.

Watch the distinction: Normal color and no visible clumps prove a returned platelet unit is acceptable. Appearance is only one check; identity, elapsed time and documented handling also matter.

45. Choosing compatible components

Choose compatibility by component, because red cells carry donor ABO antigens whereas plasma carries donor antibodies. For red-cell issue, first confirm the recipient’s ABO and Rh interpretation, then choose an ABO-compatible unit and apply the service’s Rh rules. Review historical and current antibodies: an antigen-negative unit may be needed even when its ABO group is suitable. Complete the required compatibility testing and verify any special component needs. Plasma selection reverses the ABO emphasis: donor plasma antibodies must be compatible with recipient red cells. Platelet selection includes ABO and Rh considerations, inventory and the clinical request, with the service’s rules guiding exceptions. When suitable inventory is scarce, communicate the constraint and use the authorized selection pathway. A technician should not silently replace required antibody or issue checks with an apparently convenient unit.

Worked example: A group A, Rh-positive patient needs red cells and has a documented anti-Jka. Available group A units include one Jka-positive unit and one confirmed Jka-negative unit. Both are ABO suitable, but select the Jka-negative unit and perform the required compatibility test using a valid patient specimen. If that unit is unavailable, escalate the shortage for authorized sourcing or alternative planning; do not issue the Jka-positive unit by default.

Watch the distinction: ABO compatibility settles red-cell selection. Rh status, clinically significant antibody history, antigen typing, specimen validity and the required compatibility result can each change the issue decision.

46. Component modifications

A component modification addresses a particular exposure. Leukocyte reduction removes most donor white cells, reducing selected leukocyte-related complications; it does not reliably prevent transfusion-associated graft-versus-host disease. Irradiation inactivates donor lymphocytes so they cannot proliferate in the recipient, while leaving the component’s main red-cell or platelet function available. Washing removes much of the plasma and soluble material, which can help when those contents are the problem, but it does not substitute for irradiation or antigen matching. Each modification can affect expiration, labeling or handling, so verify the final product after processing. Start with the request’s stated clinical need, identify the mechanism to address, then check ABO, Rh, antibody requirements and the modification together. An additive or special label never makes an otherwise incompatible unit suitable.

Worked example: A request specifies irradiated red cells for a patient with a stated need. Inventory contains a leukocyte-reduced compatible unit and a compatible unit that can be irradiated. Select the irradiated option after confirming its postprocessing label and applicable storage limit. The leukocyte-reduced unit alone does not meet the requested protection against donor lymphocyte proliferation, even though it removes many white cells.

Watch the distinction: Leukocyte reduction, irradiation and washing are interchangeable ways to make blood safer. They remove or alter different materials and address different risks.

47. Issue checks and emergency support

The issue step links the correct patient to the correct component at the correct time. Match patient and specimen identifiers, review ABO and Rh typing, antibody history, compatibility status, product attributes and expiration, then record the specific unit released and recipient destination. An identification discrepancy stops routine issue until resolved. Emergency release is a documented exception when waiting for complete testing would delay urgent care; it requires the authorization and component selection pathway specified by the service. Record what testing was incomplete, preserve the sample and unit links, and continue the remaining work. If subsequent testing finds incompatibility or a new antibody, promptly notify the responsible team through the urgent communication pathway and document the message. Emergency pressure increases the need for an auditable chain, because later investigation depends on it.

Worked example: An emergency request arrives before the patient’s antibody screen is complete. The service’s stated emergency-release procedure permits issue after the required clinician authorization and patient identification checks. Record the authorization, unit number, tests pending and recipient location, then continue testing. If the screen later detects a clinically significant antibody, notify the clinical team immediately, document the contact and follow the service’s next-unit selection process.

Watch the distinction: Emergency release means compatibility records can be filled in later from memory. The exception changes testing timing; identity, authorization, unit traceability and follow-up communication still require documentation.

48. Reaction investigation and service quality

When a reaction is suspected, preserve evidence while the clinical team manages the patient. Confirm that transfusion has been stopped under the response procedure, secure the unit and tubing, and compare the patient, order, unit label and issue record for a clerical mismatch. Examine pretransfusion and posttransfusion specimens for a new hemolysis pattern, then perform the directed ABO, DAT and compatibility investigations. A new positive DAT may support immune coating but is neither necessary nor sufficient to explain every reaction. Fever or rash can have several causes; a contaminated component demands a different laboratory investigation. Record specimen times, observations, results and communications. Broader laboratory quality management also includes component quarantine, recalls and lookback when a product or donor finding may affect other recipients.

Worked example: During a red-cell transfusion, a patient develops fever and back pain. Posttransfusion plasma is newly pink compared with the pretransfusion sample. Secure the remaining unit, verify patient and unit identifiers, and investigate hemolysis, DAT and compatibility as directed. The change raises concern for an acute hemolytic process, but the laboratory must check for collection-related hemolysis and other causes before assigning a reaction classification.

Watch the distinction: A positive posttransfusion DAT alone proves an acute hemolytic reaction. Compare it with the pretransfusion DAT, plasma appearance, identifiers and other findings before interpreting the event.

Reference: [2]

49. Microbiology specimen and direct examination

The diagnostic value of a culture begins with where and how the specimen was collected. A sample from a normally sterile site carries different meaning from one passing through colonized skin or mucosa. Record source, collection time, prior antimicrobial exposure and transport conditions. Direct examination can quickly describe organism shape, Gram reaction and inflammatory cells, while also revealing contamination. Many squamous epithelial cells in sputum suggest oral material; few inflammatory cells weaken evidence that it represents an infected lower airway. For a Gram stain, first verify the stain controls so an apparent Gram-negative result is not merely over-decolorization. Choose further processing according to specimen and suspected organism, and report descriptive findings rather than declaring infection from morphology alone. If quality is inadequate under the stated criteria, seek a better specimen.

Worked example: A sputum smear contains numerous squamous epithelial cells, rare neutrophils and mixed gram-positive and gram-negative flora. Its collection note says the patient produced saliva rather than a deep cough. These observations favor oral contamination. Apply the laboratory’s stated acceptance criteria before culture interpretation and request recollection if it fails. Heavy later growth from this sample should not automatically be treated as a lower respiratory isolate.

Watch the distinction: Any organism seen in sputum came from the lower airway. Oral flora and squamous cells may enter during collection, so specimen quality changes what growth can mean.

50. Common bacterial identification paths

Begin bacterial identification with a sequence of narrowing observations. A Gram stain separates broad cell-wall staining groups and shows cocci or rods; colony morphology and hemolysis add clues. For gram-positive cocci, arrangement and tests such as catalase direct the next branch, while hemolysis and additional reactions refine it. For gram-negative rods, oxidase activity helps distinguish some nonfermenters from many enteric organisms; lactose fermentation on an appropriate differential medium provides another branch. No single trait establishes a species because unrelated organisms can share it and atypical strains occur. Check pure growth before interpreting identification-system output, since mixed colonies can produce contradictory biochemical results. Confirm that controls and database limits support the identification, and refer an unusual or high-consequence pattern through the designated process.

Worked example: A pure blood-culture isolate is a gram-negative rod. It is oxidase negative and produces lactose-fermenting colonies on the stated differential medium. That combination supports an enteric identification path, so proceed with the validated biochemical or mass-spectrometric system. Do not report a named species from those three findings alone: several enteric organisms share them. If the system gives low confidence, investigate purity and use the required confirmatory steps.

Watch the distinction: Oxidase negativity plus lactose fermentation identifies one species. Those traits narrow a group; species reporting needs sufficient discriminating evidence and a valid identification method.

51. Fastidious, anaerobic and mycobacterial recovery

Recovery conditions should match the organism’s vulnerabilities. Fastidious bacteria may need enriched media or a particular atmosphere; obligate anaerobes can lose viability when exposed to oxygen, making a deep aspirate in suitable transport more useful than a surface swab. For suspected mycobacteria, decontamination reduces competing flora, concentration increases the chance of detecting sparse organisms, and acid-fast staining exploits the lipid-rich cell wall. Smear microscopy is rapid but less sensitive than culture and cannot by itself identify a species. Molecular testing can detect a target sooner, yet inhibition or an absent target can limit interpretation. Culture supports further identification but takes longer and requires appropriate containment. Review collection and transport before concluding that a negative culture excludes the suspected organism, and escalate potentially hazardous isolates through the laboratory’s containment and referral route.

Worked example: A deep aspirate from a sterile site arrives in an unsealed syringe after prolonged air exposure. The request includes anaerobic culture. Document the transport defect, notify the responsible section and obtain a suitable specimen if the stated acceptance rules require it; a negative anaerobic culture here has reduced reassurance. In a separate sputum sample, an acid-fast smear is positive, so use the designated containment and referral process while identification continues.

Watch the distinction: A negative anaerobic culture excludes anaerobes regardless of transport. Oxygen exposure, delays and unsuitable swabs can lower recovery before the sample reaches the incubator.

52. Fungi and parasites

Fungal and parasitic identification depends on structure, source and life cycle. Budding unicellular forms suggest yeast, while filamentous hyphae and reproductive structures suggest mold; some fungi can change form under different growth conditions. Colony appearance alone is often insufficient and may create an exposure hazard when a suspect mold is manipulated. Parasites require a different sequence: choose the specimen from the organism’s likely location, collect at a useful time, and use direct examination, concentration or staining as appropriate. Concentration can improve recovery of sparse eggs and cysts but may distort delicate forms, so method choice affects morphology. A single negative sample may miss intermittent shedding. Distinguish an observed egg, larva or cyst from a definitive species assignment when required diagnostic features are absent, and follow safer handling or referral instructions for concerning cultures.

Worked example: One stool sample contains an oval helminth egg with a described operculum; another patient’s direct wet mount is negative after symptoms suggest intermittent shedding. Document the egg’s measured and visible features before identification. For the negative specimen, use the case’s stated concentration method and collection schedule if indicated. A separate mold culture with features flagged for restricted handling should remain closed and be referred through the specified pathway.

Watch the distinction: A negative single wet mount rules out intestinal parasites. Low organism burden and intermittent shedding can make detection depend on collection timing and concentration.

53. Viral and molecular methods

Choose a viral test according to what it detects and when that target appears. Antigen assays detect viral proteins, nucleic-acid amplification detects a selected sequence, and serology detects the host response, which may lag exposure or persist afterward. Culture assesses recoverable organism but is slower and is not interchangeable with sequence detection. An internal amplification control helps reveal inhibition; a failed control can invalidate a negative patient result even when the instrument prints “not detected.” Contamination can instead create false positives, so physical workflow and controls matter. Mass-spectrometric identification generally characterizes an organism recovered in culture and depends on the reference database; it is not a direct substitute for a viral nucleic-acid assay. Interpret a valid positive as detection of its target, then consider specimen type, timing and clinical context.

Worked example: A respiratory swab is reported “not detected” by a nucleic-acid assay, but its internal amplification control fails while external controls pass. Treat the patient result as invalid because specimen-specific inhibition may have blocked amplification. Repeat after the stated corrective processing or request a new swab. If repeat testing detects viral RNA, report target detection; that result alone does not establish that infectious virus is present.

Watch the distinction: A printed negative molecular result is valid whenever run controls pass. The specimen’s own internal control may fail, leaving inhibition unresolved for that patient sample.

54. Susceptibility, resistance and urgent isolates

An MIC is the lowest tested drug concentration that prevents visible growth under the method’s conditions; an inhibition zone is a measured diameter around a disk. Neither number becomes “susceptible” or “resistant” without the organism-drug breakpoint and a valid test. Check organism identity, medium, inoculum, incubation, control-strain results and the case’s breakpoint table before assigning a category. Intrinsic resistance is a species-level property that can override a misleading apparent in-vitro result, while an unexpected acquired-resistance pattern may require confirmation. Do not infer a treatment regimen from a laboratory category alone; drug exposure and patient factors belong to the clinical team. If a control fails, withhold affected interpretations. An isolate designated urgent or high consequence requires prompt notification, containment and referral while confirmation proceeds.

Worked example: For a hypothetical organism-drug pair, the case defines susceptible as MIC ≤1 mg/L, intermediate as 2 mg/L and resistant as ≥4 mg/L. A patient isolate has MIC 2 mg/L, so its category is intermediate. However, the control strain’s MIC is outside its supplied acceptable range. Withhold the patient category, correct the test problem and repeat or confirm it before reporting.

Watch the distinction: A smaller MIC is automatically susceptible across all drugs and organisms. Interpretation uses the matching breakpoint, and failed controls can invalidate even a clearly measured MIC.

55. Urine collection and physical findings

Collection type determines what a urine result represents. A random specimen reflects conditions at one time; first-morning urine is often more concentrated after overnight retention; a timed collection supports excretion calculations only when all voids in the stated interval are captured. Record start and end times, total volume and any missed void. Delayed warm storage allows bacterial growth, pH change and breakdown of cells or casts. Color and clarity offer clues but are nonspecific: pigments, drugs, blood, crystals and cells can alter appearance. Specific gravity estimates density and can rise with large molecules such as glucose or radiographic contrast; refractive and reagent-strip methods respond differently to solutes. Compare results with method limits and specimen history before linking concentration or turbidity to physiology.

Worked example: A patient brings a 24-hour urine container but reports missing one afternoon void. The measured volume is 1.2 L, and an analyte concentration is 20 mg/L. Multiplication gives 20 × 1.2 = 24 mg in the received volume, but that is not the full daily excretion because collection was incomplete. The sample also stood warm overnight, so assess stability and request a complete recollection for the intended daily result.

Watch the distinction: A recorded 24-hour volume makes any daily excretion calculation valid. Missed voids and poor storage can invalidate the total even when volume and concentration are measurable.

56. Reagent-strip chemistry

A urine strip is a set of separate chemical reactions, each with a read window. Protein pads respond mainly to albumin; glucose pads use an enzymatic oxidation sequence; ketone pads detect selected ketones rather than every ketone body equally. The blood pad reacts to heme activity, whether from intact red cells, free hemoglobin or myoglobin. Nitrite suggests nitrate-reducing bacteria after sufficient bladder contact, while leukocyte esterase reflects white-cell enzyme activity. Bilirubin and urobilinogen pads offer different clues to pigment handling; pH and concentration affect several reactions. Interfering drugs, oxidants, highly colored urine and delayed reading can mislead. Verify strip storage, expiration and controls, read at the specified time, and correlate chemical results with microscopy and specimen handling before reporting a pattern.

Worked example: A promptly examined urine sample has a positive blood pad, yet no red cells are seen in several well-mixed microscopic fields. Confirm strip controls and check that the sample was not collected after a delay that could lyse cells. The reaction may reflect free hemoglobin or myoglobin, so report the verified chemical and microscopic observations and seek the laboratory’s supported follow-up rather than inventing an RBC count.

Watch the distinction: A positive blood pad means intact red cells are present. The pad responds to heme activity, so free pigment can produce a positive reaction without visible cells.

57. Urine sediment and pattern correlation

Sediment interpretation works best when structures are identified in a fresh, well-mixed specimen and correlated with the strip. Casts form in renal tubules, so a red-cell cast points more strongly toward renal bleeding than free red cells alone. Dysmorphic red cells add evidence of passage through the glomerular system, while squamous epithelial cells suggest collection contamination. White cells and bacteria may support inflammation or infection, but contamination and storage can mimic that combination. Crystals depend on pH, solute concentration and cooling; identify them by shape and, when needed, confirmatory properties rather than color alone. Distinguish true casts from mucus, fibers and other artifacts by their matrix and parallel sides. Record what is actually seen, assess specimen age and refer a concerning combined pattern for clinical interpretation.

Worked example: A fresh urine specimen has a positive protein pad. Microscopy shows dysmorphic red cells and cylindrical casts with red cells embedded in a matrix. The combined observations support a glomerular source of bleeding more strongly than isolated hematuria would. Verify the cast identity and document the findings for prompt clinical review; the laboratory pattern does not identify the underlying disease.

Watch the distinction: Any red cells in urine indicate kidney bleeding. Collection contamination and lower-tract sources are possible; morphology and red-cell casts provide more specific localization clues.

58. Cerebrospinal fluid analysis

Cerebrospinal fluid changes quickly after collection, so cell counts, chemistry and microbiology need prompt, coordinated handling. Label sequential tubes and their intended tests; a traumatic tap can add blood, while genuine intracranial bleeding can also produce a bloody sample. Compare tube appearances and counts only with collection details, because clearing across tubes is an imperfect clue. For a manual count, multiply observed cells by the dilution factor and divide by the counted chamber volume in microliters. Confirm the chamber volume and whether dilution notation means one part specimen in two parts total. Then compare the corrected count with the case’s age-appropriate reference information and correlate the differential with protein, glucose and microbial findings. Clots, degenerating cells and poor mixing can distort counts; escalate verified urgent findings through the laboratory communication pathway.

Worked example: A CSF aliquot is mixed one part specimen with one part diluent, giving a 1:2 dilution. Forty cells are counted in 0.2 µL of diluted fluid. The undiluted concentration is 40 × 2 ÷ 0.2 = 400 cells/µL. Record the calculation, then compare sequential tube counts and supplied reference information. If the specimen is bloody, do not label the elevation traumatic without considering the full collection and laboratory findings.

Watch the distinction: A falling red-cell count across CSF tubes proves a traumatic tap. It is a clue, but overlap with true bleeding and collection variation limits certainty.

59. Serous and synovial fluids

Serous-fluid interpretation often compares fluid with a paired serum sample drawn close enough in time to reflect the same physiological state. Apply only the classification criteria supplied for the case; a protein ratio is fluid protein divided by serum protein, with matching units. Cell counts and differential findings add context but do not alone establish the cause of an effusion. Synovial-fluid work starts with appearance, viscosity, cell count and microscopy. Polarized-light examination distinguishes crystals by shape and birefringence when the method is available and the observer is trained. Crystal identification can explain inflammation, yet infection can coexist, so microbiological work remains relevant when requested. Check for clots, dilution and instrument validation before interpreting counts from either fluid. Report observed patterns and refer urgent or discordant results through the stated process.

Worked example: A case defines a fluid-to-serum protein ratio above 0.5 as supporting an exudative pattern. Fluid protein is 3.6 g/dL and paired serum protein is 6.0 g/dL, so 3.6 ÷ 6.0 = 0.60; it meets that hypothetical criterion. In a separate synovial specimen, crystals are identified, but numerous neutrophils and a culture request still warrant microbiological assessment because crystals do not exclude infection.

Watch the distinction: Once synovial crystals are found, infection can be dismissed. Crystal-associated inflammation and infection can occur together, so requested cultures and other findings still matter.

60. Other body fluids and method limits

Semen and fecal tests depend heavily on collection timing and specimen integrity. For semen analysis, document collection method, completeness, elapsed time and transport conditions before assessing volume, concentration, motility or morphology under the laboratory’s validated method. A missed portion can bias a total count even if the remaining sample is measurable. Fecal tests vary in target: chemical blood testing, pathogen detection and parasite examination have different storage and contamination limits. For any nonblood body fluid, verify that an automated analyzer has been validated for that fluid type, expected cell range and possible interfering debris. A numeric display from an unvalidated matrix is not a releasable result. Use the approved manual or body-fluid method when needed, document corrections and promptly communicate verified urgent findings with patient identity and read-back as required.

Worked example: An analyzer designed for blood prints 1,800 cells/µL for a serous fluid, but that fluid is outside its validated matrix list. Withhold the number and count the sample by the approved body-fluid method. Separately, a fecal specimen for a stability-sensitive assay spent two days unrefrigerated despite a stated chilled-transport requirement. Record the handling failure and obtain an acceptable specimen before interpreting a negative result.

Watch the distinction: An instrument result is valid whenever it prints a number. Matrix effects and debris can alter counting, so body-fluid results require a method validated for that specimen.